The clinical behavior of meningiomas is variable. Because multiple growth factor receptors have been identified in these tumors, the authors sought to assess the capacity of the expression patterns of a subset of these receptors to stratify meningioma cases.
Eighty-four meningiomas were analyzed, including 36 benign, 29 atypical, and 19 malignant lesions. Immunohistochemical staining was performed for epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR)–β, basic fibroblast growth factor receptor (BFGFR), and MIB-1. Survival analyses were performed using follow-up data obtained in patients with newly diagnosed tumors.
Immunoreactivity for EGFR was observed in 47% of benign, 48% of atypical, and 42% of malignant tumors. Staining for BFGFR was identified in 89% of benign, 97% of atypical, and 95% of malignant lesions. Immunostaining for PDGFR-β was evident in all the lesions assessed. Mean MIB-1 indices for benign, atypical, and malignant cases were 3.6 (range 0.5–15.3), 8.2 (range 1.5–23.1) and 18.3 (range 1.0–55.8), respectively. Overall mean follow-up duration was 9.0 years (range 5.1–18.8 years). Lack of EGFR immunoreactivity was identified as a strong predictor of shorter overall survival in patients with atypical meningioma (p = 0.003, log-rank test). This association was not evident in cases of benign or malignant meningiomas.
There is a significant association between EGFR immunoreactivity and prolonged survival in patients with atypical meningioma. Given the variable behavior of atypical meningiomas, EGFR assessment could improve existing strategies for patient stratification and treatment.
Abbreviations used in this paper:BFGF = basic fibroblast growth factor; BFGFR = BFGF receptor; EGF = epidermal growth factor; EGFR = EGF receptor; PDGF = platelet-derived growth factor; PDGFR = PDGF receptor; WHO = World Health Organization.
Address reprint requests to: Justin S. Smith, M.D., Ph.D., Department of Neurological Surgery, University of California, San Francisco, 505 Parnassus Avenue, M-779, San Francisco, California 94143-0112. email:
AdamsEFSchrellUMFahlbuschRThieraufP: Hormonal dependency of cerebral meningiomas. Part 2: In vitro effect of steroids, bromocriptine, and epidermal growth factor on growth of meningiomas. J Neurosurg73:750–7551990
JohnsonMDWoodardAKimPFrexes-SteedM: Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. J Neurosurg94:293–3002001
LusisEAWatsonMAChicoineMRLymanMRoerigPReifenbergerG: Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res65:7121–71262005
PerryABanerjeeRLohseCMKleinschmidt-DeMastersBKScheithauerBW: A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of ana-plastic meningiomas. Brain Pathol12:183–1902002
ReubiJCHorisbergerULangWKoperJWBraakmanRLambertsSW: Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol134:337–3441989
SchrellUMGauerSKiesewetterFBickelAHrenJAdamsEF: Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extra-cellular growth factors, and PDGF-BB autocrine growth loop. J Neurosurg82:600–6071995
TakahashiJAMoriHFukumotoMIgarashiKJayeMOdaY: Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc Natl Acad Sci U S A87:5710–57141990